WST (West Pharmaceutical Services) LT-Debt-to-Total-Asset: 0.07 (As of Mar. 2026)


WST West Pharmaceutical Services Inc WST
95 GF Score
Price $341.96
GF Value $361.52
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is West Pharmaceutical Services LT-Debt-to-Total-Asset?

West Pharmaceutical Services WST +1.66% 95 LT-Debt-to-Total-Asset is 0.07 as of Mar. 2026. GuruFocus rates WST with a GF Score™ of 95/100 and a GF Value™ of $361.52 (Fairly Valued). The stock has 9 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. West Pharmaceutical Services's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.07.

West Pharmaceutical Services's long-term debt to total assets ratio declined from Mar. 2025 (0.08) to Mar. 2026 (0.07). It may suggest that West Pharmaceutical Services is progressively becoming less dependent on debt to grow their business.

West Pharmaceutical Services  (NYSE:WST) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

West Pharmaceutical Services LT-Debt-to-Total-Asset Related Terms

West Pharmaceutical Services LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for West Pharmaceutical Services's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

West Pharmaceutical Services LT-Debt-to-Total-Asset Chart

West Pharmaceutical Services Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.08 0.04 0.08 0.07

West Pharmaceutical Services Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.07 0.07 0.07 0.07
WST
95GF Score
West Pharmaceutical Services Inc WST
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

West Pharmaceutical Services LT-Debt-to-Total-Asset Calculation

West Pharmaceutical Services's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=298.4/4270
=0.07

West Pharmaceutical Services's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=294.8/4109.8
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.07 mean?
West Pharmaceutical Services (WST) has a LT-Debt-to-Total-Asset of 0.07 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on West Pharmaceutical Services and its competitors.
Is West Pharmaceutical Services' LT-Debt-to-Total-Asset too high?
West Pharmaceutical Services' current LT-Debt-to-Total-Asset is 0.07. Overall, West Pharmaceutical Services has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' LT-Debt-to-Total-Asset compare to RMD and MDLN?
West Pharmaceutical Services' LT-Debt-to-Total-Asset of 0.07 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on West Pharmaceutical Services and its competitors. West Pharmaceutical Services's current LT-Debt-to-Total-Asset is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
Based on GuruFocus' analysis, West Pharmaceutical Services (WST) is currently considered Fairly Valued. The stock's GF Value™ is $361.52, compared to a current price of $341.96 — trading 5.4% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.07. West Pharmaceutical Services' overall GF Score™ is 95/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For West Pharmaceutical Services (WST), the current LT-Debt-to-Total-Asset is 0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is West Pharmaceutical Services (WST) Overvalued in 2026?

Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued. The current stock price of $341.96 is trading 5.4% below its estimated GF Value™ of $361.52. GuruFocus considers West Pharmaceutical Services to be Fairly Valued.

Key valuation signals for WST:

  • LT-Debt-to-Total-Asset: 0.07
  • GF Value™: $361.52 vs. price of $341.96 (5.4% below fair value)
  • GF Score™: 95/100 with 9 warning signs

No single metric tells the full story. See the WST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

West Pharmaceutical Services Business Description

Address 530 Herman O. West Drive, Exton, PA, USA, 19341-1147
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
95GF Score

Get the complete analysis for WST

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$341.96
Price
$361.52
GF Value